SonoThera (TM), a biotechnology company dedicated to treating the root cause of human diseases by developing the next generation of genetic medicines, today announced it will present new data at the ...

Scientists have uncovered a surprising mechanism by which a brain enzyme called OTULIN controls the expression of tau, the protein that forms toxic tangles in Alzheimer's disease. The findings, ...

The market presents significant opportunities driven by high demand for biologics and protein therapeutics, as well as ...

One of the hallmarks of cancer cells is their ability to evade apoptosis, or programmed cell death, through changes in ...

A revolution has occurred in the field of pharmaceutical development due to the development of drugs that target membrane proteins. It is estimated that one-third of currently available drugs target G ...

The baculovirus expression vector system (BEVS) provides a versatile platform for the expression of individual recombinant proteins as well as multimeric protein complexes, virus-like particles, ...

As gene therapies continue to advance, the demand for scalable, reproducible, and efficient potency assays is rapidly increasing—especially for adeno-associated virus (AAV) vectors. Accurate ...

mRNA, widely known from the COVID-19 vaccine, is not actually a "therapeutic agent," but a technology that delivers the ...

New findings show that removing Centaurin-α1, a protein elevated in Alzheimer’s disease, significantly reduces inflammation, plaque buildup, and cognitive deficits in a well-established mouse model.

Saint Louis University’s Protein Core is a shared-use core facility that supports expression, purification and analysis of reagent and preclinical proteins. The core provides instrumentation and ...